REG - Hikma Pharmaceutical - Medium-term Group guidance ahead of US site visit

Hikma PharmaceuticalsAnnouncement

15/05/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250515:nRSO8570Ia&default-theme=true

RNS Number : 8570I  Hikma Pharmaceuticals Plc  15 May 2025

Hikma announces strong medium-term Group guidance ahead of its US site visit

 

London, 15 May 2025 - Hikma Pharmaceuticals PLC (Hikma, Group), the
multinational pharmaceutical group, is today hosting sell-side analysts and
investors at its US manufacturing and R&D facility in Columbus, Ohio. The
senior leadership teams from our Generics and Injectables segments will
present on their respective businesses, strategies, and plans to deliver
long-term, sustainable growth.

 

Attendees will tour the Group's state-of-the-art, 1,000,000 sq. ft. facility
in Columbus, which produces oral, respiratory and other generic and specialty
products. It is one of Hikma's four US manufacturing facilities producing a
broad range of medicines for patients across the US, where Hikma is one of the
largest suppliers of generic medicines. Attendees will also tour the Company's
newly acquired Injectables facility in Bedford, Ohio.

 

Alongside the event, Hikma is introducing the following medium-term guidance:

·      Group revenue growth - 6% to 8% three-year CAGR (2024 to 2027)

·      Group core operating profit growth - 7% to 9% three-year CAGR
(2024 to 2027)

 

In addition, Hikma is introducing a five-year target for Group revenue to
reach $5 billion by 2030.

 

Hikma is also announcing that its Generics business is being renamed Hikma Rx
to reflect its focus on providing differentiated and complex prescription (Rx)
medicines.

 

The presentation is available on Hikma's website at
https://www.hikma.com/investors/results-and-presentations/
(https://www.hikma.com/investors/results-and-presentations/) . A recording and
transcript of the presentation and Q&A will be made available following
the event.

 

 

- ENDS -

 

 

Enquiries:

Hikma (Investors)

 Susan Ringdal                                +44 (0)20 7399 2760/ +44 7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                             +44 (0)20 3892 4389/ +44 7795 896738

 Director, Investor Relations
 Layan Kalisse                                +44 (0)20 7399 2788/ +44 7970 709912

 Senior Associate, Investor Relations

 

FTI Consulting (media)

Ciara Martin
 
+44 (0)7779 775979

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB-/positive Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,500 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

©2025 Hikma Pharmaceuticals PLC. All rights reserved.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAESSFLFSEFA